Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.
Bladder cancer metastasis is virtually incurable with current platinum-based chemotherapy. We used the novel COXEN informatic approach for in silico drug discovery and identified NSC-637993 and NSC-645809 (C1311), both imidazoacridinones, as agents with high-predicted activity in human bladder cancer. Because even highly effective monotherapy is unlikely to cure most patients with metastasis and NSC-645809 is undergoing clinical trials in other tumor types, we sought to develop the basis for use of C1311 in rational combination with other agents in bladder cancer. Here, we demonstrate in 40 human bladder cancer cells that the in vitro cytotoxicity profile for C1311 correlates with that of NSC-637993 and compares favorably to that of standard of care chemotherapeutics. Using genome-wide patterns of synthetic lethality of C1311 with open reading frame knockouts in budding yeast, we determined that combining C1311 with a taxane could provide mechanistically rational combinations. To determine the preclinical relevance of these yeast findings, we evaluated C1311 singly and in doublet combination with paclitaxel in human bladder cancer in the in vivo hollow fiber assay and observed efficacy. By applying COXEN to gene expression data from 40 bladder cancer cell lines and 30 human tumors with associated clinical response data to platinum-based chemotherapy, we provide evidence that signatures of C1311 sensitivity exist within nonresponders to this regimen. Coupling COXEN and yeast chemigenomics provides rational combinations with C1311 and tumor genomic signatures that can be used to select bladder cancer patients for clinical trials with this agent.
Department of Urology, University of Virginia, Charlottesville, VA, USA.
Steven C
SC
Smith
Dmytro M
DM
Havaleshko
Kihyuck
K
Moon
Alexander S
AS
Baras
Jae
J
Lee
Stefan
S
Bekiranov
Daniel J
DJ
Burke
Dan
D
Theodorescu
D000465:Algorithms; D000609:Aminoacridines / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D054316:Biomarkers, Pharmacological; D003198:Computer Simulation; D004347:Drug Interactions; D004354:Drug Screening Assays, Antitumor; D020869:Gene Expression Profiling; D006801:Humans; D020128:Inhibitory Concentration 50; D008957:Models, Genetic; D017239:Paclitaxel / Q000494:pharmacology; D012441:Saccharomyces cerevisiae / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D018709:Statistics, Nonparametric; D014158:Transcription, Genetic / Q000187:drug effects; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms
D000609:Aminoacridines; D000970:Antineoplastic Agents; D054316:Biomarkers, Pharmacological; C098965:C 1311; D017239:Paclitaxel
BMC Bioinformatics. 2006 Feb 16;7:73
16483361
Clin Cancer Res. 2008 Oct 1;14(19):5984-93
18829477
Pharmacoeconomics. 2003;21(18):1315-30
14750899
Bioinformatics. 2004 Dec 12;20(18):3710-5
15297299
J Clin Oncol. 2001 Feb 1;19(3):666-75
11157016
Nat Methods. 2006 Aug;3(8):601-3
16862133
Cancer Res. 2009 Nov 1;69(21):8302-9
19843853
Nat Biotechnol. 2004 Jan;22(1):62-9
14661025
Science. 1997 Jan 17;275(5298):343-9
8994024
Neoplasia. 2004 Jan-Feb;6(1):1-6
15068665
Mol Pharmacol. 1996 May;49(5):772-80
8622625
Pharmacogenomics J. 2002;2(4):259-71
12196914
FEBS Lett. 2008 Jul 9;582(16):2467-70
18570892
Cancer Res. 1996 May 1;56(9):2094-104
8616856
Oncologist. 2005 Nov-Dec;10(10):792-8
16314289
Stat Methods Med Res. 2008 Aug;17(4):347-88
17698936
Mol Cancer Ther. 2007 Mar;6(3):820-32
17339364
Bioinformatics. 2005 Jul 1;21(13):3017-24
15840707
Eur J Cancer. 2010 Mar;46(4):729-34
20031390
Cancer. 2008 Sep 15;113(6):1284-93
18629841
J Clin Oncol. 2006 Feb 10;24(5):778-89
16432078
J Clin Oncol. 2008 Sep 20;26(27):4435-41
18802156
Life Sci. 1995;57(2):131-41
7603295
Nat Rev Cancer. 2006 Oct;6(10):813-23
16990858
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13086-91
17666531
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4407-14
17671123
Cancer Res. 2010 Mar 1;70(5):1753-8
20160033
Nat Rev Cancer. 2005 Sep;5(9):689-98
16110319
J Clin Oncol. 2000 Sep;18(17):3068-77
11001674
Br J Cancer. 1999 Sep;81(2):367-75
10496367
Mol Cancer Ther. 2007 Feb;6(2):578-86
17308055
Methods. 2007 Feb;41(2):206-21
17189863
Clin Cancer Res. 2001 Aug;7(8):2168-81
11489790
Neural Comput. 2005 Mar;17(3):731-40
15802013